1314125-01-3

Basic information

• Product Name: tetramethyl (4-methyl-phenylsulfonylamino)methyl-1,1-bisphosphonate
• Synonyms: tetramethyl (4-methyl-phenylsulfonylamino)methyl-1,1-bisphosphonate
• CAS NO: 1314125-01-3
• Molecular Weight: 401.314
• Mol File: 1314125-01-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: tetramethyl (4-methyl-phenylsulfonylamino)methyl-1,1-bisphosphonate(CAS DataBase Reference)
• NIST Chemistry Reference: tetramethyl (4-methyl-phenylsulfonylamino)methyl-1,1-bisphosphonate(1314125-01-3)
• EPA Substance Registry System: tetramethyl (4-methyl-phenylsulfonylamino)methyl-1,1-bisphosphonate(1314125-01-3)

Safety Data

• Hazardous Substances Data: 1314125-01-3(Hazardous Substances Data)

Upstream product

• 70-55-3 toluene-4-sulfonamide 
• 868-85-9 Dimethyl phosphite 

Downstream Products

• 112856-33-4 (4-methyl-phenylsulfonylamino)methyl-1,1-bisphosphonic acid 

Relevant articles and documents

Biphenyl Sulfonylamino Methyl Bisphosphonic Acids as Inhibitors of Matrix Metalloproteinases and Bone Resorption

A number of matrix metalloproteinases (MMPs), proteins important in the balance of bone remodeling, play a critical role both in cancer metastasis and in bone matrix turnover associated with the presence of cancer cells in bone. Here, we report the synthesis and biological evaluation of a new class of MMP inhibitors characterized by a bisphosphonate function as the zinc binding group. Since the bisphosphonate group is also implicated in osteoclast inhibition and provides a preferential affinity to biological apatite, the new molecules can be regarded as bone-seeking medicinal agents. Docking experiments were performed to clarify the mode of binding of bisphosphonate inhibitors in the active site of MMP-2. The most promising of the studied bisphosphonates showed nanomolar inhibition against MMP-2 and resulted in potent inhibition of osteoclastic bone resorption in vitro. Bone resorption inhibition: A series of biphenyl sulfonylamino methyl bisphosphonic acids were synthesized and tested both as matrix metalloproteinase (MMP) and bone resorption inhibitors. The most promising compound (15) showed nanomolar activity against MMP-2 and good selectivity over MMP-8, -9, and -14; furthermore, it showed a very good antiresorptive activity comparable with that of zolendronic acid.